BenevolentAI
ben best in class oral peripherally restricted potent and selective drug for the treatment of moderate severe an opportunity to differentiate on safety and a precision medicine approaches safety | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
61 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2024
ben ulcerative colitis | BenevolentAI
Results
March 2023
ben ulcerative colitis affects us population million patients in forecast market by a chronic lifelong disease that causes in and ulceration of the inner lining of the colon and rectum of patients are mild moderate of patients are moderate severe and of patients are severe fulminant of moderate severe patients do not respond to anti main treatment paradigm safety treatments have many side effects from steroids to anti and inhibitors black box warnings high unmet need for an alternative oral small molecule treatment option with improved safety pro and in treatment of refractory patients ben oral peripherally restricted inhibitor under development as a in class treatment for refractory was by our platform as an entirely novel target for the treatment of using our molecular design we designed a best in class peripherally restricted inhibitor ben ben is expected to provide an disease modifying oral treatment for ben will target moderate and severe patients meeting the unmet need left by existing therapies including patients refractory to anti or other improved safety and tolerability pro compared to competitors aiming to use a precision medicine approach to target key responder patient cohorts and avoid the safety risks associated with ineffective therapies | BenevolentAI
Investor Conference
January 2023
ben ulcerative colitis ben oral peripherally restricted inhibitor under development as a in class treatment for refractory affects us population million patients in forecast market by | BenevolentAI
Investor Presentation
October 2022
ben oral peripherally restricted inhibitor under development as a in class treatment for refractory ulcerative colitis an opportunity to differentiate on safety and a precision medicine approaches safety | BenevolentAI
Related slides by other companies
Ocuphire Pharma
Investor Day
January 2022
summary of program | Ocuphire Pharma
Alkermes
Investor Presentation
January 2023
and oral treatment option for adults with schizophrenia or bipolar i disorder | Alkermes
Ocuphire Pharma
Results
October 2022
multiple targets in treatment landscape | Ocuphire Pharma
Ocuphire Pharma
Results
October 2022
has the potential to be first line of therapy for patients efficacy signal safety non invasive treatment option guidance physician patients efficacy signal safety non invasive treatment option | Ocuphire Pharma
Other recent decks by BenevolentAI
See all presentations (11 decks)
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights